Status:
COMPLETED
Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura
Lead Sponsor:
Danish Headache Center
Conditions:
Headache, Migraine
Aura
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
To investigate the migraine inducing effect of levcromakalim in patients with migraine with aura.
Eligibility Criteria
Inclusion
- Migraine with aura patients of both sexes.
- 18-70 years.
- 50-100 kg.
Exclusion
- Headache less than 48 hours before the tests start
- Daily consumption of drugs of any kind that investigator deems might affect study results or safety.
- Pregnant or nursing women.
- Cardiovascular disease of any kind, including cerebrovascular diseases.
- Tension type headache (TTH) according to International Classification of Headache Disorders version 3 more than 5 times a month on average during the past year
- Known cluster headache according to International Classification of Headache Disorders version 3.
- Psychiatric disorder
- Smoking or abuse of drugs or alcohol
- Hypertension (systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg) on day of inclusion.
- Hypotension (systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg) on day of inclusion.
Key Trial Info
Start Date :
September 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 16 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04905654
Start Date
September 29 2021
End Date
May 16 2023
Last Update
May 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Danish Headache Center
Glostrup Municipality, Copenhagen, Denmark, DK-2600